Use of rivaroxaban in patients with stroke

D. Toni, A. Carolei, V. Caso, D. Consoli, M. Del Sette, D. Inzitari, M. Melis, G. Micieli, L. Provinciali, S. Ricci, P. Santalucia, V. Toso

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Rivaroxaban, an inhibitor of Factor Xa, is a direct oral anti-coagulant that has been found to be non-inferior to warfarin in preventing cerebral ischemia in patients with non-valvular atrial fibrillation and in the subgroup of patients with a history of the previous stroke or transient ischemic attack. Vascular neurologists in daily clinical practice may encounter patients taking rivaroxaban or patients who may benefit from its use. In this paper, we review the current clinical indications, contraindications, and clinical management guidelines for rivaroxaban while providing a special focus on neurological aspects and expert opinions on rivaroxaban therapy management in various situations that a neurologist may encounter when treating patients with an ischemic stroke (including those requiring intravenous or intra-arterial reperfusion therapy) and patients with an intracerebral hemorrhage. Since data from clinical trials and real-life data are missing in some clinical situations, strong recommendations are not always available. Nevertheless, practical guidelines should be adopted to maximize benefits from this oral anti-coagulant. © 2017, Springer-Verlag Italia.
Original languageEnglish
Pages (from-to)745-754
Number of pages10
JournalNeurological Sciences
Volume38
Issue number5
DOIs
Publication statusPublished - 2017

Fingerprint

Stroke
Coagulants
Guidelines
Factor Xa
Transient Ischemic Attack
Cerebral Hemorrhage
Expert Testimony
Warfarin
Brain Ischemia
Atrial Fibrillation
Reperfusion
Blood Vessels
Rivaroxaban
Clinical Trials
Therapeutics
Neurologists

Cite this

Toni, D., Carolei, A., Caso, V., Consoli, D., Del Sette, M., Inzitari, D., ... Toso, V. (2017). Use of rivaroxaban in patients with stroke. Neurological Sciences, 38(5), 745-754. https://doi.org/10.1007/s10072-017-2855-3

Use of rivaroxaban in patients with stroke. / Toni, D.; Carolei, A.; Caso, V.; Consoli, D.; Del Sette, M.; Inzitari, D.; Melis, M.; Micieli, G.; Provinciali, L.; Ricci, S.; Santalucia, P.; Toso, V.

In: Neurological Sciences, Vol. 38, No. 5, 2017, p. 745-754.

Research output: Contribution to journalArticle

Toni, D, Carolei, A, Caso, V, Consoli, D, Del Sette, M, Inzitari, D, Melis, M, Micieli, G, Provinciali, L, Ricci, S, Santalucia, P & Toso, V 2017, 'Use of rivaroxaban in patients with stroke', Neurological Sciences, vol. 38, no. 5, pp. 745-754. https://doi.org/10.1007/s10072-017-2855-3
Toni D, Carolei A, Caso V, Consoli D, Del Sette M, Inzitari D et al. Use of rivaroxaban in patients with stroke. Neurological Sciences. 2017;38(5):745-754. https://doi.org/10.1007/s10072-017-2855-3
Toni, D. ; Carolei, A. ; Caso, V. ; Consoli, D. ; Del Sette, M. ; Inzitari, D. ; Melis, M. ; Micieli, G. ; Provinciali, L. ; Ricci, S. ; Santalucia, P. ; Toso, V. / Use of rivaroxaban in patients with stroke. In: Neurological Sciences. 2017 ; Vol. 38, No. 5. pp. 745-754.
@article{bc475afb304e47a38f6f6551670edeb3,
title = "Use of rivaroxaban in patients with stroke",
abstract = "Rivaroxaban, an inhibitor of Factor Xa, is a direct oral anti-coagulant that has been found to be non-inferior to warfarin in preventing cerebral ischemia in patients with non-valvular atrial fibrillation and in the subgroup of patients with a history of the previous stroke or transient ischemic attack. Vascular neurologists in daily clinical practice may encounter patients taking rivaroxaban or patients who may benefit from its use. In this paper, we review the current clinical indications, contraindications, and clinical management guidelines for rivaroxaban while providing a special focus on neurological aspects and expert opinions on rivaroxaban therapy management in various situations that a neurologist may encounter when treating patients with an ischemic stroke (including those requiring intravenous or intra-arterial reperfusion therapy) and patients with an intracerebral hemorrhage. Since data from clinical trials and real-life data are missing in some clinical situations, strong recommendations are not always available. Nevertheless, practical guidelines should be adopted to maximize benefits from this oral anti-coagulant. {\circledC} 2017, Springer-Verlag Italia.",
author = "D. Toni and A. Carolei and V. Caso and D. Consoli and {Del Sette}, M. and D. Inzitari and M. Melis and G. Micieli and L. Provinciali and S. Ricci and P. Santalucia and V. Toso",
note = "Export Date: 30 October 2017 CODEN: NESCC Correspondence Address: Toni, D.; Unit{\`a} di Trattamento Neurovascolare, University La Sapienza Rome, Viale del Policlinico 155, Italy; email: danilo.toni@uniroma1.it",
year = "2017",
doi = "10.1007/s10072-017-2855-3",
language = "English",
volume = "38",
pages = "745--754",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "5",

}

TY - JOUR

T1 - Use of rivaroxaban in patients with stroke

AU - Toni, D.

AU - Carolei, A.

AU - Caso, V.

AU - Consoli, D.

AU - Del Sette, M.

AU - Inzitari, D.

AU - Melis, M.

AU - Micieli, G.

AU - Provinciali, L.

AU - Ricci, S.

AU - Santalucia, P.

AU - Toso, V.

N1 - Export Date: 30 October 2017 CODEN: NESCC Correspondence Address: Toni, D.; Unità di Trattamento Neurovascolare, University La Sapienza Rome, Viale del Policlinico 155, Italy; email: danilo.toni@uniroma1.it

PY - 2017

Y1 - 2017

N2 - Rivaroxaban, an inhibitor of Factor Xa, is a direct oral anti-coagulant that has been found to be non-inferior to warfarin in preventing cerebral ischemia in patients with non-valvular atrial fibrillation and in the subgroup of patients with a history of the previous stroke or transient ischemic attack. Vascular neurologists in daily clinical practice may encounter patients taking rivaroxaban or patients who may benefit from its use. In this paper, we review the current clinical indications, contraindications, and clinical management guidelines for rivaroxaban while providing a special focus on neurological aspects and expert opinions on rivaroxaban therapy management in various situations that a neurologist may encounter when treating patients with an ischemic stroke (including those requiring intravenous or intra-arterial reperfusion therapy) and patients with an intracerebral hemorrhage. Since data from clinical trials and real-life data are missing in some clinical situations, strong recommendations are not always available. Nevertheless, practical guidelines should be adopted to maximize benefits from this oral anti-coagulant. © 2017, Springer-Verlag Italia.

AB - Rivaroxaban, an inhibitor of Factor Xa, is a direct oral anti-coagulant that has been found to be non-inferior to warfarin in preventing cerebral ischemia in patients with non-valvular atrial fibrillation and in the subgroup of patients with a history of the previous stroke or transient ischemic attack. Vascular neurologists in daily clinical practice may encounter patients taking rivaroxaban or patients who may benefit from its use. In this paper, we review the current clinical indications, contraindications, and clinical management guidelines for rivaroxaban while providing a special focus on neurological aspects and expert opinions on rivaroxaban therapy management in various situations that a neurologist may encounter when treating patients with an ischemic stroke (including those requiring intravenous or intra-arterial reperfusion therapy) and patients with an intracerebral hemorrhage. Since data from clinical trials and real-life data are missing in some clinical situations, strong recommendations are not always available. Nevertheless, practical guidelines should be adopted to maximize benefits from this oral anti-coagulant. © 2017, Springer-Verlag Italia.

U2 - 10.1007/s10072-017-2855-3

DO - 10.1007/s10072-017-2855-3

M3 - Article

VL - 38

SP - 745

EP - 754

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 5

ER -